GlassScriptPhysician profile
Pamela H Temples
NPI 1740366442
$3,367.56
in general payments reported to CMS, 2019-2025
34 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $350 · 2021: $463 · 2022: $565 · 2023: $453 · 2024: $385 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $683.90 | 2019-2025 | Veozah |
| Abbvie INC. | $562.70 | 2019-2023 | Lo Loestrin Fe, Orilissa, Synthroid |
| Amgen INC. | $389.15 | 2019-2023 | Prolia |
| Pfizer INC. | $305.31 | 2019-2025 | |
| Myriad Women'S Health, INC. | $128.52 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $117.42 | 2019-2025 | |
| Hologic Sales and Service, LLC | $113.94 | 2020-2024 | Aptima, Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $95.74 | 2019 | |
| Novo Nordisk INC | $89.48 | 2019-2025 | Wegovy |
| Millicent US INC | $70.30 | 2020-2025 | Femlyv, Intrarosa, Femring |
| Mayne Pharma Commercial LLC | $65.48 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.33 | 2023-2024 | Xifaxan, Trulance |
| Duchesnay USA Incorporated | $61.48 | 2019 | |
| Shield Therapeutics INC | $54.85 | 2023-2024 | Accrufer |
| Avion Pharmaceuticals | $54.83 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $52.76 | 2020-2022 | |
| Baxter Healthcare | $42.44 | 2022 | |
| Daiichi Sankyo INC. | $38.28 | 2019-2020 | |
| Therapeuticsmd, INC. | $38.11 | 2019-2020 | |
| Lupin INC. | $36.41 | 2019 | |
| Sumitomo Pharma America, INC. | $35.67 | 2024 | Myfembree |
| Optumhealth Care Solutions, LLC | $35.04 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
| Davol INC. | $33.50 | 2020 | |
| Lsi Solutions INC | $29.05 | 2023-2024 | Fornisee |
| Coopersurgical, INC. | $25.90 | 2019-2021 | |
| Organon LLC | $24.20 | 2022 | |
| Roche Diagnostics Corporation | $20.17 | 2019 | |
| Agile Therapeutics, INC. | $16.25 | 2022 | |
| Allergan, INC. | $14.85 | 2019 | |
| Coloplast Corp | $14.77 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.73 | 2019 | |
| Lilly USA, LLC | $13.72 | 2024 | Zepbound |
| Olympus America INC. | $13.50 | 2019 | |
| Meditrina | $9.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Temples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.